Author

A. A. Lutckii

Observed names: A. Lutckii, Anton A. Lutckii, Anton A. Lutskiy

Institution: BIOCAD (Russia)

Observed institution: BIOCAD (Russia)

ORCID: 0000-0003-2884-1568

Observed ORCID: 0000-0003-2884-1568

OpenAlex ID: A5056377971

Totally drug‐resistant tuberculosis and adjunct therapies

2014 · S. K. Parida, R. Axelsson‐Robertson, et al. · Journal of Internal Medicine · 172

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

2021 · Nikita V. Lomakin, Bulat A. Bakirov, et al. · Inflammation Research · 58

Interferon-γ: biological function and application for study of cellular immune response

2016 · A. A. Lutckii, A. A. Zhirkov, et al. · Journal Infectology · 22

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

2021 · V. I. Mazurov, E. G. Zotkin, et al. · Rheumatology Science and Practice · 18

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

2021 · V. I. Mazurov, M. A. Korolev, et al. · Modern Rheumatology Journal · 14

Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR

2024 · V. I. Mazurov, E. L. Nasonov, et al. · Doklady Biochemistry and Biophysics · 5

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

2023 · V. I. Mazurov, A. M. Lila, et al. · Rheumatology Science and Practice · 5

SAT0040 Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-il-6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers

2018 · P. Khlyabova, A. Eremeeva, et al. · Annals of the Rheumatic Diseases · 2

Results of a Double-Blind Prospective Comparative Randomized Phase 3 Clinical Trial of the Efficacy and Safety of BCD-264 and Darzalex as Monotherapy for Relapsed/Refractory Multiple Myeloma (BCD-264-2/DARVIVA)

2026 · T. V. Shelekhova, J. Kumar, et al. · Clinical oncohematology · 1

Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies

2022 · N. V. Lomakin, B. A. Bakirov, et al. · Biological Products Prevention Diagnosis Treatment · 1

Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS

2026 · Nikolay N. Murashkin, Andrey L. Bakulev, et al. · Вопросы современной педиатрии

Extract of oak bark as a selective natural reagent for the spectrophotometric determination of iron (II) in pharmaceutical preparations and blood serum

2025 · V. I. Mazurov, A. M. Lila, et al. · Rheumatology Science and Practice

Pos0649 Efficacy and Safety of Levilimab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis: 1-year Results of Phase Iii, Double-blind, Placebo-controlled, Randomized Trial

2022 · V. Mazurov, M. Korolev, et al. · Annals of the Rheumatic Diseases

Works count: 13

Citation count: 298

H-index: 5

I10-index: 5